Novo Nordisk announced on April 14 a strategic partnership with OpenAI covering R&D, manufacturing, supply chain, and commercial operations, with the stated goal of compressing timelines from drug candidate identification to patient. The deal is molecule-agnostic and does not target a specific pipeline asset; pilot programs will run across all divisions with full integration targeted by end of 2026. Novo Nordisk, which has been losing share to Eli Lilly in the GLP-1 market, will also use the partnership to upskill its global workforce on AI tooling.